Neuburgh Advisers LLC lowered its stake in shares of Masimo Co. (NASDAQ:MASI) by 51.5% during the 2nd quarter, HoldingsChannel.com reports. The firm owned 4,544 shares of the medical equipment provider’s stock after selling 4,832 shares during the quarter. Neuburgh Advisers LLC’s holdings in Masimo were worth $676,000 at the end of the most recent quarter.
Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. FMR LLC lifted its position in Masimo by 7.4% in the first quarter. FMR LLC now owns 4,178,808 shares of the medical equipment provider’s stock worth $577,845,000 after buying an additional 289,246 shares during the last quarter. Bank of New York Mellon Corp raised its stake in shares of Masimo by 10.6% in the second quarter. Bank of New York Mellon Corp now owns 694,217 shares of the medical equipment provider’s stock valued at $103,312,000 after acquiring an additional 66,444 shares during the period. Janus Henderson Group PLC raised its stake in shares of Masimo by 17.2% in the second quarter. Janus Henderson Group PLC now owns 691,953 shares of the medical equipment provider’s stock valued at $102,976,000 after acquiring an additional 101,354 shares during the period. Geode Capital Management LLC lifted its holdings in shares of Masimo by 14.6% in the 4th quarter. Geode Capital Management LLC now owns 547,027 shares of the medical equipment provider’s stock worth $58,734,000 after acquiring an additional 69,627 shares during the last quarter. Finally, Prudential Financial Inc. lifted its holdings in shares of Masimo by 3.6% in the 2nd quarter. Prudential Financial Inc. now owns 543,060 shares of the medical equipment provider’s stock worth $80,818,000 after acquiring an additional 18,892 shares during the last quarter. 84.07% of the stock is currently owned by hedge funds and other institutional investors.
MASI has been the subject of a number of recent analyst reports. BidaskClub cut shares of Masimo from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, August 6th. BTIG Research reissued a “hold” rating on shares of Masimo in a research report on Thursday, August 1st. UBS Group raised their price objective on shares of Masimo from $172.00 to $180.00 and gave the stock a “buy” rating in a research note on Thursday, August 1st. Piper Jaffray Companies boosted their target price on Masimo from $148.00 to $160.00 in a research report on Friday, May 17th. Finally, Stifel Nicolaus upped their target price on Masimo from $165.00 to $170.00 and gave the company a “buy” rating in a research note on Thursday, August 1st. One investment analyst has rated the stock with a hold rating and six have issued a buy rating to the stock. Masimo currently has a consensus rating of “Buy” and a consensus target price of $159.25.
MASI stock traded up $2.90 during midday trading on Wednesday, reaching $148.51. The company’s stock had a trading volume of 106,851 shares, compared to its average volume of 264,268. Masimo Co. has a 1 year low of $98.23 and a 1 year high of $160.25. The firm has a market capitalization of $7.77 billion, a price-to-earnings ratio of 49.01, a PEG ratio of 2.32 and a beta of 1.22. The stock has a fifty day simple moving average of $153.13 and a two-hundred day simple moving average of $141.90.
Masimo (NASDAQ:MASI) last issued its earnings results on Wednesday, July 31st. The medical equipment provider reported $0.76 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.73 by $0.03. The firm had revenue of $229.60 million during the quarter, compared to analyst estimates of $222.46 million. Masimo had a net margin of 22.15% and a return on equity of 17.82%. The business’s revenue was up 8.5% on a year-over-year basis. During the same period in the previous year, the firm earned $0.73 earnings per share. On average, equities research analysts predict that Masimo Co. will post 3.15 earnings per share for the current fiscal year.
In other Masimo news, EVP Yongsam Lee sold 258 shares of the firm’s stock in a transaction on Thursday, June 27th. The stock was sold at an average price of $145.00, for a total transaction of $37,410.00. Following the transaction, the executive vice president now directly owns 73,736 shares in the company, valued at approximately $10,691,720. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Anand Sampath sold 30,000 shares of Masimo stock in a transaction on Friday, June 14th. The shares were sold at an average price of $142.39, for a total value of $4,271,700.00. Following the sale, the executive vice president now directly owns 27,518 shares of the company’s stock, valued at $3,918,288.02. The disclosure for this sale can be found here. Insiders have sold a total of 238,738 shares of company stock valued at $36,108,247 in the last quarter. 11.50% of the stock is currently owned by company insiders.
Masimo Corporation, a medical technology company, develops, manufactures, and markets noninvasive monitoring technologies worldwide. The company offers Masimo Signal Extraction Technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry.
Featured Article: Momentum Indicator: Relative Strength Index
Want to see what other hedge funds are holding MASI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Masimo Co. (NASDAQ:MASI).
Receive News & Ratings for Masimo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Masimo and related companies with MarketBeat.com's FREE daily email newsletter.